【摘要】 目的探讨多药耐药基因蛋白P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶-π(GST-π)及DNA拓扑异构酶Ⅱ(TopoⅡ)在乳腺癌中的表达及其临床意义。方法用免疫组化法检测52例未经抗肿瘤治疗的原发乳腺癌中P-gp、GST-π及TopoⅡ的表达水平。结果52例乳腺癌组织中P-gp、GST-π和TopoⅡ表达率分别为57.7%、53.8%和76.9%,P-gp、GST-π和TopoⅡ的表达与组织学类型、年龄无关(P>0.05),与临床分期、淋巴结转移有显著性差异(P<0.05),P-gp和GST-π的表达呈显著正相关(P<0.05),P-gp和TopoⅡ的表达呈明显负相关(P<0.05),GST-π和TopoⅡ呈明显负相关(P<0.05)。结论乳腺癌化疗前检测P-gp、GST-π及TOPOⅡ耐药基因蛋白,对肿瘤的化疗药物选择及判断预后有一定的价值。更多还原

【Abstract】 Objective To explore the expression and clinical significance of P-glycoprotein (P-gp), Glutathione- s- transferase -π(GST-π) and Topo Ⅱ in breast carcinoma tissue.Methods The expression level of P-glycoprotein (P-gp), Glutathione-s-transferase -π(GST-π)and Topo Ⅱ in the operating samples from 52 cases with untreated primary breast carcinomas were detected with immunohistochemical method.Results Positive expression rates of P-gp, GST-π and Topo Ⅱin 52 cases of breast carcinoma were 57.7%(30/52)、53.8%(28/52)and 76.9%(40/52). The positive expression of P-gp, GST-π and Topo Ⅱ was no relationship with histological type and patients’ age (P<0.05),and which was significant associated with clinical stage and lymph node metasis(P<0.05) .P-gp significantly positively correlation with GST-π(P<0.05), P-gp negatively related to Topo Ⅱ(P<0.05), GST-π had obviously negative correlation with Topo Ⅱ(P<0.05).Conclusion Before chemotherapy to patients with breast carcinoma,the test of resistance drug gene will help doctors select the mechanisms of drug and to evaluate prognosis of breast carcinoma.更多还原